化学療法: オープンアクセス
オープンアクセス
ISSN: 2167-7700
ISSN: 2167-7700
Mohamad Luthfi
Background: Body weight change commonly occurs in breast cancer patients who receive adjuvant chemotherapy. However, there was lack of information associated with weight loss and hematological parameter change. The purpose of this study was to evaluate the body weight and hematological parameter change following adjuvant chemotherapy in advanced breast cancer. Methods: This prospective observational study included 50 advanced breast cancer (Stage IIIB and stage IV) subject who were receiving adjuvant chemotherapy with Doxorubicin and Cyclophosphamide regiment. Body weight, Body Mass Index (BMI), Body Surface Area (BSA) and hematological parameter were measured before the onset of chemotherapy, then after first and second cycles of chemotherapy. Results: Based on the study results, the subject body weight was decrease after first and second cycles chemotherapy from 60.06 ± 11.16 kg to 61.33 ± 16.61 and 58.69 ± 10.41 kg (p<0.05), respectively. The BMI was also decrease from 25.66 ± 4.10 kg/m2 to 25.33 ± 4.12 and 25.05 ± 4.12 kg/m2 (p<0.05), respectively. Body surface area also decrease from 1.58 ± 0.16 m2 to 1.58 ± 0.16 and 1.57 ± 0.15 m2 (p<0.05), respectively. Hemoglobin and Total Lymphocyte Count (TLC) level significantly decrease after first and second cycles of chemotherapy. Hemoglobin level decrease from 12.04 ± 1.35 g/dL to 11.29 ± 1.32 and 10.97 ± 1.47 g/dL (p<0.05), and TLC decrease from 2235.61 ± 701.02/mm3 to 1916.42 ± 670.77 and 1894.82 ± 712.13/mm3 (p<0.05), respectively. There was no significant decrease in leukocyte and Absolute Neutrophil Count (ANC) level after first and second cycles of chemotherapy (p=0.06 and p=0.56). Conclusion: Body weight, BMI and BSA significantly decrease after first and second cycles of chemotherapy. Hemoglobin and TLC level also significantly decrease but there is no significant decrease in leukocyte and ANC level. Appropriate nutritional management interventions with follow-up programs are needed.